Penn

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

Retrieved on: 
화요일, 11월 29, 2022
Oncology, Health, Surgery, Clinical Trials, Research, Science, Biotechnology, Indocyanine green, NCI, NIR, MIS, ICG, SBIR, University, National Cancer Institute, Stanford University School of Medicine, Patient, Neoplasm, Penn, Cardiothoracic surgery, Small business, Standard of care, Lung cancer, Thorax, Surgeon, Journal of Surgical Research, NIH, Research, Family, Cathepsin, Division, Trial of the century, Safety, Pharmaceutical industry, Medical imaging

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).
  • The grant will help fund a Phase 2 clinical study evaluating the companys targeted fluorescent imaging agent, VGT-309, for intraoperative imaging of tumors in patients undergoing lung cancer surgery.
  • We are grateful to the NCI for their support and to the team at the University of Pennsylvanias Perelman School of Medicine for conducting this Phase 2 study.
  • The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.

Verismo Therapeutics Establishes R&D Center in Philadelphia to Drive KIR-CAR Platform Forward

Retrieved on: 
화요일, 11월 29, 2022
Laboratory, Verismo (literature), Therapy, Patient, Penn, Research, State Farm Research and Development Center, CAR, Development, CIC, Vaccine, Verismo

PHILADELPHIA, Nov. 29, 2022 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced its new Research and Development Center located at CIC Philadelphia. Verismo plans to use this space to facilitate its R&D and process development capabilities to further advance its novel KIR-CAR platform.

Key Points: 
  • PHILADELPHIA, Nov. 29, 2022 /PRNewswire/ -- Verismo Therapeutics , a clinical-stage CAR-T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced its new Research and Development Center located at CIC Philadelphia.
  • Verismo plans to use this space to facilitate its R&D and process development capabilities to further advance its novel KIR-CAR platform.
  • Verismo's highly equipped laboratories at CIC Philadelphia will allow the company to rapidly progress its pipeline with minimal delay and expenditure.
  • This new R&D space will allow them to apply their expertise to drive our product platform forward," said Dr. Bryan Kim, CEO of Verismo.

Stagwell Heads to CES 2023: Transforming Marketing Through Impactful Technology

Retrieved on: 
수요일, 11월 16, 2022
Las Vegas Convention Center, Advertising, Technology, NFT, IMC Content Studio, CTA, NEW, Consumer Technology Association, Marketing, NASDAQ, LAS, LVCC, Science, Central Hall, Melbourne, CES, Penn, Nightclub, Public relations, Mark Penn

NEW YORK and LAS VEGAS, Nov. 16, 2022 /PRNewswire/ -- Stagwell (NASDAQ: STGW), the challenger network built to transform marketing, will attend CES 2023 hosted by the Consumer Technology Association (CTA)®, taking place Jan. 5-8, 2023 in Las Vegas. Stagwell experts and client partners will discuss transforming marketing through impactful technology across a variety of activations at the annual consumer technology expo.

Key Points: 
  • Stagwell experts and client partners will discuss transforming marketing through impactful technology across a variety of activations at the annual consumer technology expo.
  • Stagwell experts and client partners will discuss transforming marketing through impactful technology.
  • "Stagwell transforms marketing through impactful technology, driving measurable outcomes for our clients' businesses and for society at large," said Stagwell Chairman and CEO Mark Penn.
  • If you're a journalist interested in connecting with Mark Penn, Stagwell corporate leaders, or executives from Stagwell agencies in attendance, please email [email protected] .

ClutchBet Appoints New Vice President of Engineering

Retrieved on: 
수요일, 11월 16, 2022
Advertising, The Meet Group, JD, Library, Knowledge, Pennsylvania State University, Warner Bros., Running, BS, Peter Head (civil engineer), VP, DramaFever, Software engineer, University of Massachusetts Lowell, IOS, Penn, Sport, Physics, State, Engineering

DENVER, Nov. 16, 2022 /PRNewswire/ -- ClutchBet, America's new mobile-first online sportsbook, is pleased to announce the appointment of Joshua Auriemma as Vice President of Engineering.

Key Points: 
  • DENVER, Nov. 16, 2022 /PRNewswire/ -- ClutchBet, America's new mobile-first online sportsbook, is pleased to announce the appointment of Joshua Auriemma as Vice President of Engineering.
  • An industry-leader in building and scaling sportsbooks, Josh joins Clutchbet from Penn Interactive, the online subsidiary of Penn Entertainment.
  • Josh grew Penn's engineering department from a team of one to over 300 engineers across multiple disciplines.
  • In addition to Iowa, ClutchBet also holds market access agreements in Colorado, Louisiana and Indiana and is progressing licensing in those markets.

Exploding Kittens Launches New Game with Award-Winning Magician Penn Jillette

Retrieved on: 
화요일, 11월 1, 2022
Entertainment, Retail, Other Entertainment, General Entertainment, Celebrity, Specialty, Code, CEO, Penn, Family, Nintendo Switch, Eye, Netflix, IOS, Bad Things, Friends, Android, Multimedia, Xbox, Penn & Teller, Penn Jillette, Entertainment, Kickstarter

Today, Exploding Kittens , leading entertainment and gaming company, announced the launch of its new game, You Lying Sack, which is a first-of-its-kind collaboration with Penn Jillette of the legendary magic-duo Penn & Teller.

Key Points: 
  • Today, Exploding Kittens , leading entertainment and gaming company, announced the launch of its new game, You Lying Sack, which is a first-of-its-kind collaboration with Penn Jillette of the legendary magic-duo Penn & Teller.
  • View the full release here: https://www.businesswire.com/news/home/20221101005469/en/
    Exploding Kittens and Penn Jillette of the legendary magic-duo Penn & Teller today launched a new game, You Lying Sack, an honest-to-goodness game about lying where players either bluff or tell the truth.
  • Everything you love about Penn is in this box, said Elan Lee, CEO and Co-Creator of Exploding Kittens.
  • Today, there are nearly 30 games available for purchase, an exclusive Exploding Kittens mobile game for Netflix subscribers, a free-to-play app, Kitty Letter, and an Exploding Kittens mobile app available on iOS , Android , and Nintendo Switch .

Carisma Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 37th Anniversary Annual Meeting

Retrieved on: 
화요일, 11월 1, 2022
Security (finance), Annual report, Penn, U.S. Securities and Exchange Commission, SITC, SEC, FIH, Clinical trial, Research, Prospectus, Securities Act of 1933, AND, CAR, HER2, University, Cell, Telephone, Sale, Form, Immunotherapy, Annual general meeting, Therapy, PARTIES, Patient, 2021 Essex County Council election, Society, Shareholder, SEC filing, Internet, ALL, Society for Immunotherapy of Cancer, Medical imaging, Mitsubishi Carisma

Accepted abstracts include: two abstracts of clinical trial data, including one for oral presentation; four abstracts of pre-clinical study data; and one abstract overviewing the design of a Phase 1 clinical trial for CT-0508.

Key Points: 
  • Accepted abstracts include: two abstracts of clinical trial data, including one for oral presentation; four abstracts of pre-clinical study data; and one abstract overviewing the design of a Phase 1 clinical trial for CT-0508.
  • "We are excited to participate at the SITC 37th Anniversary Annual Meeting so we can share the latest updates from our landmark CT-0508 trial," said Steven Kelly, Chief Executive Officer of Carisma Therapeutics.
  • "Across the seven abstracts we will be presenting, we are eager to share the promising clinical and pre-clinical updates and the advances within the Carisma Therapeutics pipeline."
  • Presentation and posters will be available on the SITC 37th Anniversary Annual Meeting portal for registered attendees.

GlassView Appoints University of Pennsylvania Professor of Neuroscience, Psychology and Marketing to its Advisory Board

Retrieved on: 
화요일, 11월 1, 2022
Well, Anthropology, Marketing, Goal, Global Brands Group, CEO, MIT, Founder, Health, Penn, Motivation, Cognitive neuroscience, Science, Vogue (magazine), Efficiency, Center, Duke, Yale University, Research, Industry, Harvard University, Department of Defense Serum Repository, United States Air Force Scientific Advisory Board, Department, Leadership, NYU, Ulta Beauty, Government of France, Psychology, Doctor of Philosophy, National, Sociology, Machine learning, Pei Partnership Architects, Creative, Advisory board, China Institute for Innovation and Development Strategy, Beauty, Management, Video game console, Defense

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- GlassView, the world's largest independent video advertising distribution platform, today announced that Michael L. Platt, director of Wharton Neuroscience Initiative and co-founder of neuroscience wearables company, Cogwear, will join its Advisory Board. Platt, who has led extensive research about the biological mechanisms that underlie decision-making and their applications to business, will lend his expertise to GlassView's ongoing work to build brand-consumer connections at the deepest levels.

Key Points: 
  • His work has been supported by the National Institutes of Health and the Department of Defense, among others.
  • "We are ecstatic to have Professor Platt join our board to help us build out unique offerings for our client base.
  • Through emotion-based targeting and optimization, high frequency trading (SmartGamma) and delivery across connected devices, GlassView is best known for its performance.
  • Launched in 2014, GlassView has headquarters in Dallas, with offices in New York City, Tokyo, Singapore, London, and Paris, among other locations.

Loulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency Disorder

Retrieved on: 
월요일, 10월 31, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Secondary research, Epilepsy, Alliance, Peripheral nervous system, View, Observational study, Genome, MRNS, Food, Neurodevelopmental disorder, Therapy, Research, Partnership, Biogen, PTC Therapeutics, Penn, Genetic disorder, Disability in Canada, Patient, Binary relation, Biology, Spasm, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BIIB, Foundation, CDKL5, UCB, Ultragenyx, RARE, University, National Clinical Assessment Service, Communication, Program, Neuron, Seizure, Life, Incidence, Frasier, Pharmaceutical industry, CDD, Medicine

The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.

Key Points: 
  • The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study.
  • The CANDID study is directed by a novel consortium of seven biopharmaceutical industry partners, together with the Loulou Foundation , to enable the development of disease-modifying therapeutics for CDD.
  • The Loulou Foundation serves as the study coordinator, while the seven partners share the funding and governance of this study involving CDD clinical centers worldwide.
  • CDKL5 Deficiency Disorder (CDD) is a neurodevelopmental disorder caused by loss-of-function mutations in the CDKL5 gene, which encodes a kinase necessary for the proper function of neurons.

Stagwell (STGW) to Participate in the 2022 RBC Capital Markets Global Technology, Internet, Media & Telecom Conference

Retrieved on: 
금요일, 10월 28, 2022
RBC Capital Markets, Mark Penn, Internet, Telecommunication, Penn, SSA Global Technologies, Science, NASDAQ, Conference, Marketing

NEW YORK, Oct. 28, 2022 /PRNewswire/ -- Stagwell (NASDAQ: STGW) announced today that Chairman and CEO Mark Penn will present at the upcoming 2022 Global Technology, Internet, Media and Telecommunications Conference hosted in New York by RBC Capital Markets on November 15 and 16, 2022.

Key Points: 
  • NEW YORK, Oct. 28, 2022 /PRNewswire/ -- Stagwell (NASDAQ: STGW) announced today that Chairman and CEO Mark Penn will present at the upcoming 2022 Global Technology, Internet, Media and Telecommunications Conference hosted in New York by RBC Capital Markets on November 15 and 16, 2022.
  • Penn will participate in a fireside chat at 3:10PM on Tuesday November 15 and is available for 1:1 investor meetings throughout the duration of the event.
  • Visit this page to view upcoming investor events and programming from Stagwell.
  • We deliver scaled creative performance for the world's most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing.

Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

Retrieved on: 
수요일, 10월 26, 2022
SEC, Company, University, Virus, Penn, Science Publishing Group, MD, Doctor of Philosophy, Private Securities Litigation Reform Act, Nasdaq, Cancer, Center, Intellectual property, Tumor microenvironment, Patient, Pathology, Medical laboratory, HSV, Immunogenic cell death, GLOBE, Enlightenment, Therapy, Transgene, Perelman School of Medicine at the University of Pennsylvania, Biology, Content discovery platform, Partnership, CADL, Vaccine, Fellow of the Academy of Medical Sciences, Candel, Immunotherapy

Herpes simplex virus (HSV) vectors containing selected transgenes based on Candel's enLIGHTEN Discovery Platform will be evaluated in combination with investigational CAR-T cell therapies in tumor models.

Key Points: 
  • Herpes simplex virus (HSV) vectors containing selected transgenes based on Candel's enLIGHTEN Discovery Platform will be evaluated in combination with investigational CAR-T cell therapies in tumor models.
  • Under the terms of the agreement, the parties will collaborate to use novel engineered viruses that break down barriers to CAR-T therapies and to evaluate the effects of these combinations in tumor models.
  • Candel is a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies.
  • Candel has established two viral immunotherapy platforms based on novel, genetically modified adenovirus and HSV constructs, respectively.